Shots:

• The US FDA and EMA has received ODD to Galecto’s GB0139 for the treatment of IPF. GB0139 showed significant reduction of YKL-40 biomarker in fibrosis- inflammation- tissue remodeling diseases in its first clinical study after 14 days of treatment
• The EMA cited GB0139’s clinically relevant biomarker data in IPF patients which provides financial incentives- encouraging the development of drugs targeting rare diseases
• GB0139 (formerly TD139) is an inhaled galectin-3 inhibitor- being evaluated in P-IIb GALACTIC-1 study in 450 patients with IP across 100 centers in the US the EU and Canada

- ­ Ref: PRNewswire | Image: Galecto